The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Caplin Point Laboratories's current ratio for the quarter that ended in Mar. 2026 was 6.70.
Caplin Point Laboratories has a current ratio of 6.70. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Caplin Point Laboratories's Current Ratio or its related term are showing as below:
NSE:CAPLIPOINT'
s Current Ratio Range Over the Past 10 Years
Min: 1.58 Med: 5.76 Max: 7.1
Current: 6.7
During the past 13 years, Caplin Point Laboratories's highest Current Ratio was 7.10. The lowest was 1.58. And the median was 5.76.
NSE:CAPLIPOINT's Current Ratio is ranked better than 90.75% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs NSE:CAPLIPOINT: 6.70
Caplin Point Laboratories (NSE:CAPLIPOINT) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Caplin Point Laboratories Current Ratio Related Terms
Caplin Point Laboratories Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CAPLIPOINT vs ZTS, UTHR: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caplin Point Laboratories Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's Current Ratio distribution charts can be found below:
* The bar in red indicates where Caplin Point Laboratories's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caplin Point Laboratories (NSE:CAPLIPOINT) has a Current Ratio of 6.70 as of Mar. 2026. This is 16% above median its historical median of 5.76. Over the past decade, Caplin Point Laboratories' Current Ratio has ranged from 1.58 to 7.10. According to the industry distribution chart, Caplin Point Laboratories ranks #92 out of 995 companies in the Drug Manufacturers industry, placing it in the top 9.2%.
Is Caplin Point Laboratories' Current Ratio too high?
Caplin Point Laboratories' current Current Ratio of 6.70 is 16% above median its 10-year median of 5.76. Over the past 10 years, this metric has ranged from a low of 1.58 to a high of 7.10. The Drug Manufacturers industry median Current Ratio is 2.00. Caplin Point Laboratories' value of 6.70 is 235% above this industry median. Based on the distribution chart, Caplin Point Laboratories ranks #92 out of 995 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Caplin Point Laboratories has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Caplin Point Laboratories ranks #92 out of 995 companies for Current Ratio. This places Caplin Point Laboratories in the top 9% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Caplin Point Laboratories' value of 6.70 is 235% above this benchmark. Historically, Caplin Point Laboratories' own Current Ratio has ranged from 1.58 to 7.10 over the past decade. While the company's 10-year median is 5.76 vs. the industry median of 2.00, Caplin Point Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caplin Point Laboratories's current Current Ratio of 6.70 is 235% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caplin Point Laboratories's current Current Ratio is 6.70, which is 16% above median its own 10-year median of 5.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,073.29, compared to a current price of ₹2,626.00 — trading 26.7% above its estimated fair value. The current Current Ratio is 6.70, which is 16% above median its 10-year median of 5.76 and 235% above the Drug Manufacturers industry median of 2.00. Caplin Point Laboratories' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current Current Ratio is 6.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?
Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued.
The current stock price of ₹2,626.00 is trading 26.7% above its estimated GF Value™ of ₹2,073.29.
GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:CAPLIPOINT:
Current Ratio: 6.70 (16% above median its 10-year median of 5.76)
GF Value™: ₹2,073.29 vs. price of ₹2,626.00 (26.7% above fair value)
Industry Position: 235% above the Drug Manufacturers median (#92 of 995)
No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
89GF Score
Get the complete analysis for NSE:CAPLIPOINT
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CAPLIPOINT has been successfully added to your 
